Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Non-Current Liabilities (2019 - 2025)

Ascendis Pharma A's Total Non-Current Liabilities history spans 5 years, with the latest figure at $252.6 million for Q4 2023.

  • For Q4 2023, Total Non-Current Liabilities fell 62.21% year-over-year to $252.6 million; the TTM value through Dec 2023 reached $252.6 million, down 62.21%, while the annual FY2023 figure was $254.0 million, 63.22% down from the prior year.
  • Total Non-Current Liabilities for Q4 2023 was $252.6 million at Ascendis Pharma A, down from $668.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $668.4 million in Q4 2022 and bottomed at $35.0 million in Q4 2019.
  • The 5-year median for Total Non-Current Liabilities is $115.5 million (2021), against an average of $235.3 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 478.88% in 2022 before it crashed 62.21% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $35.0 million in 2019, then surged by 200.65% to $105.3 million in 2020, then increased by 9.7% to $115.5 million in 2021, then surged by 478.88% to $668.4 million in 2022, then tumbled by 62.21% to $252.6 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Total Non-Current Liabilities are $252.6 million (Q4 2023), $668.4 million (Q4 2022), and $115.5 million (Q4 2021).